OSE Immunotherapeutics (XPAR:OSE) ROCE % : 136.05% (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OSE Immunotherapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was 136.05%.

OSE Immunotherapeutics ROCE % Historical Data

The historical data trend for OSE Immunotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics ROCE % Chart

OSE Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-1.80

-24.10

-19.50

-20.73

-30.30

OSE Immunotherapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-3.49	-38.83	-31.80	-32.31	136.05

OSE Immunotherapeutics ROCE % Calculation

OSE Immunotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-21.026	/	( ( (91.781 - 16.268)	+	(82.054 - 18.799) )	/ 2 )
	=	-21.026	/	( (75.513	+	63.255)	/ 2 )
	=	-21.026	/	69.384
	=	-30.30 %

OSE Immunotherapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	127.064	/	( ( (82.054 - 18.799)	+	(140.921 - 17.386) )	/ 2 )
	=	127.064	/	( ( 63.255	+	123.535 )	/ 2 )
	=	127.064	/	93.395
	=	136.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

OSE Immunotherapeutics (XPAR:OSE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OSE Immunotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OSEp:UK 0RAD:UK 6OP:Germany

Address

22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website

http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics Headlines

No Headlines